-+ 0.00%
-+ 0.00%
-+ 0.00%

Arrowhead says CHMP backs EU approval of REDEMPLO for familial chylomicronemia syndrome

PUBT·04/24/2026 10:39:23
Listen to the news
Arrowhead says CHMP backs EU approval of REDEMPLO for familial chylomicronemia syndrome
  • Arrowhead Pharmaceuticals reported a positive EMA CHMP opinion recommending EU authorization for REDEMPLO (plozasiran) to lower triglycerides in adults with familial chylomicronemia syndrome.
  • European Commission decision on marketing authorization is expected in Q2 2026.
  • Recommendation was supported by Phase 3 PALISADE results showing meaningful triglyceride lowering with fewer acute pancreatitis events versus placebo.
  • Results were already presented at ESC Congress 2024 and at American Heart Association Scientific Sessions 2024.
  • If cleared, REDEMPLO would be first siRNA medicine authorized in EU for both genetically confirmed and clinically diagnosed adult FCS patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604240639BIZWIRE_USPR_____20260423_BW566221) on April 24, 2026, and is solely responsible for the information contained therein.